VASOTEC IV SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

ENALAPRILAT

متاح من:

SANDOZ CANADA INCORPORATED

ATC رمز:

C09AA02

INN (الاسم الدولي):

ENALAPRIL

جرعة:

1.25MG

الشكل الصيدلاني:

SOLUTION

تركيب:

ENALAPRILAT 1.25MG

طريقة التعاطي:

INTRAVENOUS

الوحدات في الحزمة:

2ML

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

ملخص المنتج:

Active ingredient group (AIG) number: 0118001001; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2008-04-03

خصائص المنتج

_ _
VASOTEC
®
IV
Page 1 of 30
PRODUCT MONOGRAPH
Pr
VASOTEC
® IV
ENALAPRILAT INJECTION
1.25 MG/ML IN 2 ML VIALS
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Sandoz Canada Inc.
Date of Revision: September 20, 2013
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
SUBMISSION CONTROL NO: 167061
_ _
VASOTEC
®
IV
Page 2 of 30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY
PRODUCT
INFORMATION
..............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
........................................................................................................................
4
ADVERSE
REACTIONS
.........................................................................................................................................
7
DRUG
INTERACTIONS
........................................................................................................................................
13
DOSAGE
AND
ADMINISTRATION
....................................................................................................................
14
OVERDOSAGE
......................................................................................................................................................
15
ACTION
AND
CLINICAL
PHARMACOLOGY
...................................................................................................
15
STORAGE
AND
STABILITY
................................................................................................................................
17
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING
...........................